Jefferies Sees a Double in Incyte (INCY) on Xeljanz Label and Pricing are
Tweet Send to a Friend
Jefferies boosted its price target on Incyte (NASDAQ: INCY) from $31 to $37 after the FDA approved the Jak inhibitor ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
